Reference number(s)
1722-H

SPECIALTY QUANTITY LIMIT PROGRAM

SPRYCEL (dasatinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Sprycel (dasatinib) 20 mg tablets	90 tablets per 30 days	Adult patients: • Chronic phase CML: 100 mg orally once daily • Accelerated phase CML, myeloid or lymphoid blast phase CML: 140 mg orally once daily • Ph+ ALL: 140 mg orally once daily Pediatric patients with chronic phase CML or Ph+ ALL: • 40 mg -100 mg based on body weight
Sprycel (dasatinib) 50 mg tablets	30 tablets per 30 days	
Sprycel (dasatinib) 70 mg tablets	30 tablets per 30 days	
Sprycel (dasatinib) 80 mg tablets	30 tablets per 30 days	
Sprycel (dasatinib) 100 mg tablets	30 tablets per 30 days	
Sprycel (dasatinib) 140 mg tablets	30 tablets per 30 days	

* ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; Ph+: Philadelphia chromosome positive

III. REFERENCES

1. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; December 2018.

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

CVS caremark™